Verena Friedl
Verena Friedl
PhD Candidate, UC Santa Cruz Genomics Institute, University of California Santa Cruz
Verified email at ucsc.edu
Title
Cited by
Cited by
Year
Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study
R Aggarwal, J Huang, JJ Alumkal, L Zhang, FY Feng, GV Thomas, ...
Journal of Clinical Oncology 36 (24), 2492, 2018
2282018
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance
JJ Alumkal, D Sun, E Lu, TM Beer, GV Thomas, E Latour, R Aggarwal, ...
Proceedings of the National Academy of Sciences 117 (22), 12315-12323, 2020
112020
PLATYPUS: A Multiple—View Learning Predictive Framework for Cancer Drug Sensitivity Prediction
K Graim, V Friedl, KE Houlahan, JM Stuart
BIOCOMPUTING 2019: Proceedings of the Pacific Symposium, 136-147, 2018
62018
Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer
R Aggarwal, GR Romero, V Friedl, A Weinstein, A Foye, J Huang, F Feng, ...
Prostate cancer and prostatic diseases 24 (1), 81-87, 2021
32021
Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer
DH Kwon, L Zhang, DA Quigley, A Foye, WS Chen, CK Wong, FY Feng, ...
Urologic Oncology: Seminars and Original Investigations 38 (12), 931. e9-931 …, 2020
32020
Using transcriptional signatures to find cancer drivers with LURE
D Haan, R Tao, V Friedl, IN Anastopoulos, CK Wong, AS Weinstein, ...
bioRxiv, 727891, 2019
12019
Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway
J Carrot-Zhang, X Yao, S Devarakonda, A Deshpande, JS Damrauer, ...
Cell reports 34 (5), 108707, 2021
2021
ADRB2 expression in progressive metastatic castration-resistant prostate cancer.
D Kwon, L Zhang, A Foye, WS Chen, FY Feng, A Bailey, J Huang, ...
Journal of Clinical Oncology 38 (6_suppl), 145-145, 2020
2020
Intermediate atypical carcinoma (IAC): A discrete subtype of metastatic castration-resistant prostate cancer (mCRPC) suggesting that treatment-associated small cell …
EJ Small, RR Aggarwal, V Friedl, A Weinstein, GV Thomas, LD True, ...
Journal of Clinical Oncology 38 (6_suppl), 158-158, 2020
2020
Clinical and genomic hallmarks of low PSA secretors in metastatic castration-resistant prostate cancer (mCRPC).
G Rubio Romero, A Weinstein, V Friedl, A Foye, D Playdle, A Sabol, P Li, ...
Journal of Clinical Oncology 37 (15_suppl), 5051-5051, 2019
2019
DNA repair mutations and treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) as hallmarks of distinct subgroups of metastatic castration resistant prostate …
RR Aggarwal, P Lloyd, J Huang, TM Beer, L Zhang, GV Thomas, LD True, ...
Journal of Clinical Oncology 36 (15_suppl), 5039-5039, 2018
2018
LURE PSB Supplemental Methods
D Haan, R Tao, V Friedl, IN Anastopoulos, CK Wong, AS Weinstein, ...
The system can't perform the operation now. Try again later.
Articles 1–12